Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nucor Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Nucor Corporation trades at $272.98 (market cap $62.54B). The key difference: Nucor Corporation is far larger — about 72.4× Amphastar Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.82% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NUE | |
|---|---|---|
Market Cap | $863.95M | $62.54B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $274.74 |
52-Week Low | $16.87 | $131.78 |
Enterprise Value | $1.26B | $66.95B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Nucor (NUE) trades at $272.63, up 0.23% on the day, with a bullish technical outlook supported by moving averages and strong resistance near $280. Recent Q2 2026 earnings beat expectations with EPS of $4.84 versus $4.46, driven by record steel shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections at $36.1B. The stock is near its consensus price target of $279.63, with analyst sentiment leaning bullish (59% buy ratings).
Outlook: Nucor benefits from resilient steel demand and operational efficiency, but faces risks from tariff policies and cyclical industry pressures. The current P/E of 21.76 is reasonable given earnings growth, though net margins have compressed from 2022 peaks. Investors should monitor Q3 2026 results against the $5.72 EPS estimate for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
